GlassScriptPhysician profile
Ayse Ece Cali Daylan
NPI 1720509557
$1,872.72
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.13 · 2022: $525 · 2023: $925 · 2024: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.94 |
| Education | $182.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $373.79 | 2022-2023 | |
| Exelixis INC. | $336.17 | 2023-2024 | Cabometyx |
| Seagen INC. | $287.93 | 2022-2023 | Tukysa |
| Regeneron Healthcare Solutions, INC. | $250.00 | 2022-2023 | Libtayo |
| Abbvie INC. | $209.87 | 2023-2024 | Venclexta |
| Novartis Pharmaceuticals Corporation | $156.40 | 2023-2024 | |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $122.43 | 2023 | |
| Karyopharm Therapeutics INC. | $11.13 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayse Ece Cali Daylan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.